Search Results
Your search for ,LTD matches 290 pages
Showing 201 - 250New Data Reported From International Studies of Lung Cancer Treatment
At the European Society for Medical Oncology (ESMO) 2018 Congress, important studies were presented for every cancer type. Here, The ASCO Post offers some snapshots of lung cancer studies that may inform approaches to treating this common cancer, which—despite the advances in recent years—remains...
Atezolizumab Plus Chemotherapy Improves Outcomes in Small Cell Lung Cancer
ATEZOLIZUMAB (TECENTRIQ), an anti–program cell death ligand 1 (PD-L1) antibody, combined with carboplatin/ etoposide as first-line treatment for extensive-stage small-cell lung cancer (SCLC) improved overall and progression-free survival and may represent a new standard of care, according to...
Expert Point of View: John K. Field, PhD, FRCP
“This wonderful result joins other landmark studies. The differential effect by gender is extremely important,” said formal discussant of the trial, John K. Field, PhD, FRCP, of the University of Liverpool, UK. “This study validates the management protocol and analysis of nodule volume and growth...
Long-Term Outcomes With Anti–PD-L1 Treatment in Metastatic Triple-Negative Breast Cancer
In a long-term follow-up of a phase I trial reported in JAMA Oncology, Emens et al found that single-agent atezolizumab (Tecentriq) produced enduring benefit in patients with metastatic triple-negative breast cancer after stable or responding disease and in first-line treatment. Study Details In...
Pertuzumab and Trastuzumab Plus Chemotherapy in HER2-Positive, Metastatic Gastric or Gastroesophageal Junction Cancer
As reported in The Lancet Oncology by Tabernero et al, the phase III JACOB trial showed no significant overall survival benefit of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) plus chemotherapy in first-line treatment of HER2-positive metastatic gastric or gastroesophageal junction...
Bevacizumab Treatment Beyond Disease Progression in Advanced NSCLC
As reported in JAMA Oncology by Gridelli et al, the phase IIIB AvaALL trial did not show improved overall survival with continued bevacizumab (Avastin) treatment beyond disease progression in patients with advanced non–small cell lung cancer (NSCLC), although some improvements in subsequent...
University of Pittsburgh Medical Center to Assist Cancer Center in Beijing
To meet the growing demand for high-quality cancer care in China, Tahoe Hospital Management Co Ltd has reached a 5-year agreement with the University of Pittsburgh Medical Center (UPMC) where health-care professionals from the Pennsylvania-based medical center will assist in the planning and...
Prognostic Model for Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma
In a study reported in JAMA Oncology, Hauschild et al identified baseline lactate dehydrogenase (LDH), performance status, disease burden, and gene signature as potential determinants of treatment outcomes in BRAF V600–mutant metastatic melanoma treated with BRAF and/or MEK inhibitors. Study ...
ASCO, Conquer Cancer Congratulate 2018 Grant and Award Recipients
ASCO’s Conquer Cancer Foundation presented more than $7.3 million in grants and awards to exceptional oncology researchers at the 2018 ASCO Annual Meeting. ASCO and Conquer Cancer congratulate the recipients and offer their profound thanks to those who generously supported these awards. Visit...
Atezolizumab Plus Chemotherapy Extends Survival in Squamous NSCLC Regardless of PD-L1 Level
Patients with advanced squamous non–small cell lung cancer (NSCLC) had a greater benefit from first-line treatment with the combination of atezolizumab (Tecentriq) plus chemotherapy vs chemotherapy alone in the randomized, phase III, IMpower131 clinical trial.1 At the landmark of 12-month...
Barbara L. McAneny, MD, Inaugurated as 173rd President of the AMA
Barbara L. McAneny, MD, an oncologist from Albuquerque, has been sworn in as the 173rd President of the American Medical Association (AMA). She will focus her tenure on the AMA’s three strategic arcs: attacking the dysfunction in health care by removing obstacles and barriers that interfere...
2018 ASCO: Phase III SANDPIPER Trial Evaluates Taselisib Plus Fulvestrant in Advanced Breast Cancer
In a phase III clinical trial, the investigational PI3K inhibitor taselisib combined with standard hormone therapy fulvestrant (Faslodex) halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone. In addition, the novel combination decreased the chance of...
2018 ASCO: IMpower 131 Studies Addition of Atezolizumab to Chemotherapy in Advanced Squamous NSCLC
Initial findings from a randomized phase III clinical trial showed that patients with advanced squamous non–small cell lung cancer (NSCLC) benefit more from initial treatment with the programmed cell death ligand 1 (PD-L1)-targeted immunotherapy atezolizumab (Tecentriq) and chemotherapy than...
Conquer Cancer Foundation Sparks Global Oncology Innovation and Partnerships With IIG and IDEA Awards
ASCO’s Conquer Cancer Foundation has announced the recipients of its 2018 International Innovation Grants (IIG) and International Development and Education Awards (IDEA). Both the grant and award support oncology professionals in low-and middle-income countries, investing in either an innovative...
FDA Grants Orphan Drug Designation to YS-ON-001 for the Treatment of Pancreatic Cancer
On February 26, Yisheng Biopharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer. YS-ON-001 is a clinical-stage immuno-oncology biologic product with...
Atezolizumab Plus Bevacizumab Improves Progression-Free Survival in First-Line Treatment of Advanced Renal Cell Carcinoma
THE TYROSINE KINASE inhibitor sunitinib (Sutent) has been the mainstay of treatment for first-line treatment of advanced renal cell carcinoma for about a decade. The IMmotion151 study reported at the 2018 Genitourinary Cancers Symposium found that the combination of the immune checkpoint inhibitor...
Adjuvant Vemurafenib in Resected BRAF V600–Mutant Melanoma
In the international phase III BRIM8 trial reported in The Lancet Oncology, Maio et al found inconclusive evidence of benefit of adjuvant vemurafenib treatment in patients with BRAF V600–mutant melanoma. Study Details In the double-blind trial, 498 patients with fully resected...
FDA Grants Orphan Drug Designation to YS-ON-001 for the Treatment of Pancreatic Cancer
On February 26, Yisheng Biopharma Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer. YS-ON-001 is a clinical-stage immuno-oncology biologic product...
Long-Term Outcomes With PD-L1 Inhibition in Metastatic Urothelial Cancer
As reported by Petrylak et al in JAMA Oncology, long-term follow-up of patients in a phase I study expansion cohort indicated enduring clinical benefit and maintained tolerability of atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma. Study Details The study involved...
Monoclonal Antibody Treatment in Newly Diagnosed Pediatric High-Grade Glioma
In a phase II study reported in the Journal of Clinical Oncology, Grill et al found that the addition of bevacizumab (Avastin) to radiotherapy plus temozolomide (RT + TMZ) did not improve event-free survival in pediatric patients with newly diagnosed high-grade glioma. Study Details In the...
2018 GU CANCERS SYMPOSIUM: Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer—With Fewer Side Effects
In a phase III clinical trial of patients with previously untreated metastatic renal cell cancer combining the immunotherapy atezolizumab (Tecentriq) with the targeted therapy bevacizumab (Avastin) delayed cancer growth by about 3 months longer than sunitinib, another targeted therapy. The benefit...
Addition of Tumor-Treating Fields to Maintenance Temozolomide in Glioblastoma
Final results of a phase III trial reported by Stupp and colleagues in JAMA indicate that adding antimitotic treatment with tumor-treating fields to maintenance temozolomide is associated with improved progression-free and overall survival in patients with previously treated glioblastoma. The...
BE PREPARED TO ENCOURAGE HPV VACCINATION
“Human papillomavirus (HPV) vaccination coverage lags behind coverage for the other vaccines recommended for preteens,” according to the Centers for Disease Control and Prevention (CDC).1 A recent report about vaccination coverage in the United States among adolescents aged 13 to 17 found that...
For HPV Vaccine to Have Optimal Impact, ‘Provider Hesitancy’ Must Be Overcome
Honoring National Cancer Institute researchers Douglas R. Lowy, MD, and John T. Schiller, PhD, with the Lasker-DeBakey Clinical Medical Research Award for advances in technology that enabled the development of human papillomavirus (HPV) vaccines to prevent cervical cancer and other tumors caused by ...
ASTRO Welcomes New Officers to Board of Directors
THE MEMBERS of the American Society for Radiation Oncology (ASTRO) have elected three new officers to ASTRO’s Board of Directors and three members to serve on the medical society’s Nominating Committee. The newly elected President-Elect, Health Policy Council Vice-Chair, Science Council Vice-Chair, ...
Emerging Global Leaders in Biosimilar Development: Regulatory Guidance and Cost Impact
BIOLOGICS PLAY A KEY ROLE in cancer treatment and are the principal components of many therapeutic regimens.1 However, they require complex manufacturing processes, resulting in high cost and occasional shortages in supply, limiting the accessibility of cancer treatment for many patients, more so ...
Expert Point of View: Frank Sinicrope, MD
FRANK SINICROPE, MD, Professor of Oncology and Co-Leader of the GI Cancer Program at the Mayo Clinic, Rochester, said CHARTA addressed whether patient outcomes can be improved with a triplet regimen plus bevacizumab (Avastin) vs a standard doublet plus bevacizumab. This was based upon the finding...
First Oncologist Elected AMA President, Barbara L. McAneny, MD, Advocates for Access to Health Care for Everyone
Since the founding of the American Medical Association (AMA) in 1847, Barbara L. McAneny, MD, is the fourth woman and first oncologist to be elected President of the venerable medical association. “I’m a generic Midwesterner. I was born in Missouri and raised in Madison County, Illinois, and went...
Scalp Cooling to Prevent Chemotherapy-Induced Alopecia: Is It Now Ready for Prime Time?
In oncology, sometimes we forget about the small, everyday things that can significantly impact a patient’s life. When patients are explained the side effects of chemotherapy and chemotherapy-induced alopecia, most women will cry or become visibly upset. When a woman loses her hair, it represents...
Two Studies Show Scalp Cooling Reduces Hair Loss in Women Receiving Chemotherapy for Breast Cancer
An interim analysis of the SCALP trial, reported in JAMA by Julie Nangia, MD, of Baylor College of Medicine, and colleagues, showed that use of a scalp-cooling device significantly reduced hair loss in women receiving chemotherapy for stage I or II breast cancer compared with no scalp cooling.1 The ...
Brentuximab Vedotin vs Physician’s Choice in CD30-Positive Cutaneous T-Cell Lymphoma
The phase III ALCANZA trial has shown that brentuximab vedotin (Adcetris) produces a higher global response rate vs physician’s choice of therapy in previously treated CD30-positive cutaneous T-cell lymphomas. These results were reported by Prince et al in The Lancet. Study Details In this...
Oncologist Barbara L. McAneny, MD, FASCO, MACP, Elected AMA President-Elect
Physicians gathered at the Annual Meeting of the American Medical Association (AMA) elected Barbara L. McAneny, MD, FASCO, MACP, an oncologist from Albuquerque, New Mexico, as the new President-Elect of the physicians’ organization. Following a year-long term as President-Elect, Dr. McAneny will...
High-Dose First-Line Trastuzumab Maintenance in Metastatic HER2-Positive Gastric Cancer
As reported in the Journal of Clinical Oncology by Shah et al, the phase IIIB HELOISE trial has shown no survival benefit of high-dose vs standard trastuzumab (Herceptin) maintenance plus chemotherapy in the first-line treatment of metastatic gastric or gastroesophageal junction adenocarcinoma....
Oncologist Barbara L. McAneny, MD, FASCO, MACP, Elected AMA President-Elect
Physicians gathered at the Annual Meeting of the American Medical Association (AMA) elected Barbara McAneny, MD, FASCO, MACP, an oncologist from Albuquerque, New Mexico, as the new President-Elect of the physicians' organization. Following a year-long term as President-Elect, Dr. McAneny will...
ASCO 2017: The APHINITY Trial: Adding a Second HER2 Blocker May Lower Chance of Invasive Breast Cancer for Some Women
A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests the addition of a second HER2-targeted medicine, pertuzumab (Perjeta), to standard-of-care trastuzumab (Herceptin) after surgery may improve outcomes, although the benefit is modest. The study was presented by von...
Japanese Phase III Trial of Alectinib vs Crizotinib in ALK-Positive NSCLC
The Japanese phase III J-ALEX trial has shown improved progression-free survival with alectinib (Alecensa) vs crizotinib (Xalkori) in ALK inhibitor–naive patients with ALK-positive non–small-cell lung cancer (NSCLC). Results were reported by Hida et al in The Lancet. Study Details In...
Ongoing Phase III Clinical Trials of Immunotherapy in Advanced Non–Small Cell Lung Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on immunotherapy in lung cancer. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov. Study Title: A Randomized, Double-Blind, Phase...
Effect of Scalp-Cooling Device on Hair Loss in Women Receiving Chemotherapy for Breast Cancer
An interim analysis of the SCALP trial, reported in JAMA by Nangia et al, showed that use of a scalp-cooling device significantly reduced hair loss in women receiving chemotherapy for stage I or II breast cancer compared with no scalp cooling. The study was stopped early on the basis of efficacy....
Randomized Trial Demonstrates Benefit of Scalp-Cooling in Prevention of Chemotherapy-Induced Hair Loss
A scalp-cooling device was found safe and effective in preventing chemotherapy-induced hair loss in women undergoing adjuvant treatment for breast cancer in an interim analysis of the first prospective, randomized trial of a modern scalp-cooling system. The study was presented at the 2016 San...
2017 GI Cancers Symposium: Nivolumab Demonstrated Efficacy and Improved Survival in Patients With Previously Treated Advanced Gastric Cancer
Results of the ONO-4538-12 trial demonstrated that nivolumab (Opdivo) significantly reduced the risk of death by 37% (hazard ratio [HR] = 0.63; P < .0001) in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current ...
Atezolizumab Improves Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer
In the phase III OAK trial reported in The Lancet by Rittmeyer et al, treatment with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) improved overall survival vs docetaxel in previously treated non–small cell lung cancer (NSCLC). Results of the trial...
Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions
Memorial Sloan Kettering Cancer Center, Rockefeller University, and Weill Cornell Medicine have announced that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd and health-care investment firms Bay City Capital ...
Notable Gains in Survival Achieved With Atezolizumab in Non–Small Cell Lung Cancer
The programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) significantly improved overall survival, compared to docetaxel, in previously treated, advanced non–small cell lung cancer (NSCLC), according to preliminary results of the phase III OAK study. The findings are the first...
ASCO, Conquer Cancer Foundation Congratulate 2016 Grant and Award Recipients
The Conquer Cancer Foundation of ASCO (CCF) presented more than $6.1 million in grants and awards to nearly 250 promising oncology researchers at the 2016 ASCO Annual Meeting. The Conquer Cancer Foundation and ASCO congratulate the recipients on their contributions to the field of oncology and...
Phase III Trial Shows Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL
In the phase III GADOLIN trial reported in The Lancet Oncology, Laurie H. Sehn, MD, Chair, British Columbia Cancer Agency Lymphoma Tumor Group, and Clinical Associate Professor at the University of British Columbia, Vancouver, and colleagues, found that adding the anti-CD20 antibody obinutuzumab...
Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL
In the phase III GADOLIN trial reported in The Lancet Oncology, Sehn et al found that adding the anti-CD20 antibody obinutuzumab (Gazyva) to bendamustine (Bendeka, Treanda) increased progression-free survival in patients with rituximab-refractory indolent non-Hodgkin lymphoma (NHL). Outcomes in...
ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships
ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately...
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Anti–PD-L1 Antibody Atezolizumab Active in Previously Treated Advanced Urothelial Carcinoma
In a phase II trial reported in The Lancet, Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab produced durable responses in a marked proportion of patients with previously treated...
CancerLinQ Completes Agreements With 36 ‘Vanguard’ Practices
CancerLinQ LLC announced on April 21 that it has completed agreements with 36 oncology practices from around the country to begin implementing CancerLinQ™, the groundbreaking health information technology platform that will harness big data analytics to help oncologists rapidly improve high-quality ...
